Diplomat Pharmacy CEO on Specialization, Aiding Patients Post-IPO

Diplomat Pharmacy celebrates its initial public offering and first day of trading on the New York Stock Exchange under the ticker 'DPLO.' Diplomat chairman and chief executive Phil Hagerman details how the company's focus on specialization helped the company transition itself from a neighborhood pharmacy to the largest independent specialty pharmacy in the U.S. Hagerman weighs in on the company's business strategy, which is patient-focused and factored into the company's decision not to sell cigarettes or other tobacco products nearly 20 years before CVS-Caremark pulled tobacco products from its shelves. Hagerman also talks the pricing of Diplomat's shares, which came in below the initial range, and how the company aims to grow in the future.